medicina58巻1号

2021年01月発行

特集 エキスパートに学ぶ—最新の循環器治療薬の使い方 循環器common diseaseの治療を再考する

抗がん剤に伴う心筋障害（腫瘍循環器学）

著者： 小宮山知夏¹ 鍵山暢之²³

所属機関： ¹国家公務員共済組合連合会虎の門病院循環器センター内科 ²順天堂大学保健医療学部デジタルヘルス遠隔医療研究開発講座 ³順天堂大学医学部循環器内科

ページ範囲：P.120 - P.126

Question 1
心筋障害をきたす抗がん剤にはどのようなものがありますか？

参考文献

1）Moslehi JJ, et al：Cardiovascular toxic effects of target cancer therapies. N Engl J Med 375：1457-1467, 2016

2）Yeh ETH, et al：Cardiovascular complications of cancer therapy. J Am Coll Cardiol 53：2231-2247, 2009

3）Herrmann J, et al：Evaluation and management of patients with heart disease and cancer；Cardio-oncology. Mayo Clin Proc 89：1287-1306, 2014

4）Cardinale D, et al：Curing cancer, saving the heart；A challenge that cardioncology should not miss. Curr Cardiol Rep 18：51, 2016

5）Cardinale D, et al：Trastuzumab-induced cardiotoxicity；Clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28：3910-3916, 2010

6）Sawaya H, et al：Early detection and prevention of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 107：1375-1380, 2011

7）Zamorano JL, et al：2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under auspices of the ESC Committee for Practice Guidelines. Eur Heart J 37：2768-2801, 2016

8）Negishi K, et al：Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardior 26：493-498, 2013

9）Husam Abdel-Qadir, et al：Prevention, detection, and management of chemotherapy-related cardiac dysfunction. Can J Cardiol 32：891-899, 2016

10）Cardinale D, et al：Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114：2474-2481, 2006

11）Gulati G, et al：Neurohormonal blockade and circulating cardiovascular biomarkers during anthracycline therapy in breast cancer patients；Results from the PRADA（Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy）Study. J Am Heart Assoc 6：e006513, 2017

12）Annelies H, et al：Angiotensin Ⅱ-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer. A randomized clinical trial. JAMA Oncol 2：1030-1037, 2016

13）Pituskin E, et al：Multidisciplinary approach to novel therapies in cardio-oncology research（MANTICORE 101-Breast）；A randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 35：870-877, 2017

14）Guglin M, et al：Randomized trial of lisinopril vs. carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol 73：2859-2868, 2019

15）Brown SA, et al：The role of angiotensin-converting enzyme inhibitors and b-blockers in primary prevention of cardiac dysfunction in breast cancer patients. J Am Heart Assoc 9：e015327, 2020

16）ClinicalTrials.gov：S1501 Carvedilol in preventing cardiac toxicity in patients with metastatic HER-2-positive breast cancer　https://clinicaltrials.gov/ct2/show/NCT03418961?id=NCT03418961（2020年10月閲覧）